α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Active alpha-synuclein proteins

Alpha Synuclein: New Species – The Science of Parkinson's

Frontiers Modeling Parkinson's Disease With the Alpha-Synuclein Protein

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

Alpha Synuclein Assay

Dopamine Stabilization and Neurodegeneration with Alpha Synuclein Oligomers

α-Synuclein Aggregation in Treatment of Parkinson's Disease

HTRF Phospho-A-Synuclein Ser129 aggregation

Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)

The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease - Benskey - 2016 - Journal of Neurochemistry - Wiley Online Library

Alpha-Synuclein aggregation HTRF kit